NCT04941937

Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM

Status unknown Phase 2 Last updated 27 February 2023

What this trial tests

Phase 2 trial testing Selinexor in Multiple Myeloma in 90 participants. Status unknown.

Timeline

27 January 2022

Primary endpoint
30 December 2025

30 December 2025

Quick facts

Lead sponsor	Juan Du
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	90
Start date	27 January 2022
Primary completion	30 December 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

• Selinexor
• Thalidomide (THALIDOMIDE) — full drug profile →
• Lenalidomide — full drug profile →
• Pomalidomide — full drug profile →
• Dexamethasone (dexamethasone) — full drug profile →

Conditions studied

• Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Juan Du

Who can join

Adults 18 to 75, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Multiple myeloma (MM) is an incurable plasma cell cancer that almost all patients eventually relapse despite advancement in treatment strategies. B-cell maturation antigen (BCMA) is a cell surface receptor that expressed primarily by malignant and normal plasma cells. This is a single-arm that includes three arms, Selinexor(ATG-010) in Combination with Immunomodulator (Thalidomide/ Pomalidomide/ Lenalidomide）and Dexamethasone to Treat Relapsed/Refractory Multiple Myeloma Patients. To evaluate efficacy and safety of Selinexor in combination with Immunomodulator and Dexamethasone in RRMM patients received at least one prior lines of therapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Selinexor: Targeting a novel pathway in multiple myeloma.
   Mo CC, Yee AJ, Midha S, Hartley-Brown MA, et al · · 2023 · cited 20× · PMID 37601856 · DOI 10.1002/jha2.709
2. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.
   Abramson HN. · · 2023 · cited 12× · PMID 36768967 · DOI 10.3390/ijms24032645
3. Ikaros Proteins in Tumor: Current Perspectives and New Developments.
   Xia R, Cheng Y, Han X, Wei Y, et al · · 2021 · cited 12× · PMID 34950704 · DOI 10.3389/fmolb.2021.788440
4. The Role of Belantamab Mafodotin, Selinexor, and Melflufen in Multiple Myeloma.
   McCurdy A, Visram A. · · 2022 · cited 8× · PMID 36417082 · DOI 10.1007/s11899-022-00682-4
5. Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.
   Aumann WK, Kazi R, Harrington AM, Wechsler DS. · · 2024 · cited 3× · PMID 39161560 · DOI 10.3389/or.2024.1427497
6. Modulation of anti-tumour immunity by XPO1 inhibitors.
   Fisher JG, Bartlett LG, Kashyap T, Walker CJ, et al · · 2025 · cited 2× · PMID 40291981 · DOI 10.37349/etat.2025.1002310
7. Prognostic and functional role of the nuclear export receptor 1 (XPO1) in gastrointestinal cancers: a potential novel target?
   Sokolova V, Gruber R, Pammer LM, Kocher F, et al · · 2024 · cited 1× · PMID 39729162 · DOI 10.1007/s11033-024-10169-5
8. Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.
   Peng L, Shan T, Zhou X, Feng Z, et al · · 2025 · PMID 40496494 · DOI 10.2147/ott.s516486